BG61900B1 - Нови пролекарства за терапия на тумори и възпалителнизаболявания - Google Patents

Нови пролекарства за терапия на тумори и възпалителнизаболявания Download PDF

Info

Publication number
BG61900B1
BG61900B1 BG101290A BG10129097A BG61900B1 BG 61900 B1 BG61900 B1 BG 61900B1 BG 101290 A BG101290 A BG 101290A BG 10129097 A BG10129097 A BG 10129097A BG 61900 B1 BG61900 B1 BG 61900B1
Authority
BG
Bulgaria
Prior art keywords
compound
formula
amino
alkyl
glycosyl
Prior art date
Application number
BG101290A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101290A (en
Inventor
Klaus Bosslet
Joerg Czech
Manfred Gerken
Rainer Straub
Claude Monneret
Jean-Claude Florent
Frederic Schmidt
Original Assignee
Hoechst Akitengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61900(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Akitengesellschaft filed Critical Hoechst Akitengesellschaft
Publication of BG101290A publication Critical patent/BG101290A/xx
Publication of BG61900B1 publication Critical patent/BG61900B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
BG101290A 1996-03-12 1997-03-06 Нови пролекарства за терапия на тумори и възпалителнизаболявания BG61900B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (2)

Publication Number Publication Date
BG101290A BG101290A (en) 1997-09-30
BG61900B1 true BG61900B1 (bg) 1998-09-30

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101290A BG61900B1 (bg) 1996-03-12 1997-03-06 Нови пролекарства за терапия на тумори и възпалителнизаболявания

Country Status (24)

Country Link
US (1) US5935995A (fr)
EP (1) EP0795334B1 (fr)
JP (1) JP4392065B2 (fr)
KR (1) KR100466467B1 (fr)
CN (1) CN1168733C (fr)
AT (1) ATE316799T1 (fr)
AU (1) AU708202B2 (fr)
BG (1) BG61900B1 (fr)
BR (1) BRPI9701248B1 (fr)
CA (1) CA2199664C (fr)
CZ (1) CZ297994B6 (fr)
DE (1) DE59712561D1 (fr)
DK (1) DK0795334T3 (fr)
ES (1) ES2257756T3 (fr)
HU (1) HU228764B1 (fr)
NO (1) NO320322B1 (fr)
NZ (1) NZ314368A (fr)
PL (1) PL189604B1 (fr)
RO (1) RO120951B1 (fr)
RU (1) RU2191021C2 (fr)
SG (1) SG50011A1 (fr)
SI (1) SI0795334T1 (fr)
TR (1) TR199700178A2 (fr)
UA (1) UA50719C2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
AU772153B2 (en) * 1999-02-12 2004-04-08 Molecular Insight Pharmaceuticals, Inc. Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CA2372720C (fr) 1999-05-04 2007-09-11 John Antony Kanis Glycosides d'androgenes et activite androgenique desdits glycosides
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2003020029A1 (fr) 2001-08-30 2003-03-13 Chemocentryx, Inc. Arylamines utilises en tant qu'inhibiteurs de la liaison de la chemokine a us28
EP1541579A1 (fr) * 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Promedicament, utilisation de ce dernier en medecine et procede de production de ce promedicament
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2006038070A2 (fr) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions et methodes de modulation des canaux ioniques commandes par porte
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
RU2527531C2 (ru) * 2007-04-06 2014-09-10 Зайофарм Онколоджи, Инк. Соли изофосфорамидного иприта и его аналогов
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011028135A1 (fr) * 2009-09-02 2011-03-10 Auckland Uniservices Limited Inhibiteurs de kinases, formes promédicaments de ceux-ci et leur utilisation en thérapie
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
LT3380124T (lt) 2015-11-25 2024-06-25 Ligachem Biosciences Inc. Konjugatai, apimantys savaime skaidančias grupes, ir su jais susiję būdai
JP7327899B2 (ja) 2015-11-25 2023-08-16 レゴケム バイオサイエンシズ， インク． 分岐リンカーを含む抗体－薬物複合体及びそれらに関連する方法
KR20180077300A (ko) 2015-11-25 2018-07-06 주식회사 레고켐 바이오사이언스 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법
TWI814699B (zh) 2015-12-04 2023-09-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11654197B2 (en) 2017-03-29 2023-05-23 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
CA3099680A1 (fr) 2018-05-09 2019-11-14 Legochem Biosciences, Inc. Compositions et methodes associees a des conjugues anticorps-medicaments anti-cd19
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
EP0454783B1 (fr) * 1989-01-23 1995-06-07 Akzo Nobel N.V. Activation in vivo specifique a un site de medicaments therapeutiques
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
ES2069955T3 (es) * 1991-10-25 1995-05-16 Tungsram Reszvenytarsasag Lampara de descarga de baja presion con un solo casquillo.
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (fr) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation de promedicaments a base de glycuroconjugues au moyen de conjugues du ligand-beta-glucoronidase, utilises en chimiotherapie
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (fr) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
NZ314368A (en) 1998-10-28
BRPI9701248B1 (pt) 2022-01-18
HUP9700579A2 (en) 1997-12-29
AU1620597A (en) 1997-09-18
MX9701832A (es) 1998-07-31
AU708202B2 (en) 1999-07-29
DK0795334T3 (da) 2006-06-06
NO320322B1 (no) 2005-11-21
NO971116D0 (no) 1997-03-11
RU2191021C2 (ru) 2002-10-20
BG101290A (en) 1997-09-30
KR970065550A (ko) 1997-10-13
CN1163895A (zh) 1997-11-05
JP4392065B2 (ja) 2009-12-24
CN1168733C (zh) 2004-09-29
ATE316799T1 (de) 2006-02-15
SG50011A1 (en) 1998-06-15
DE59712561D1 (de) 2006-04-13
BR9701248A8 (pt) 2013-06-18
EP0795334A3 (fr) 1997-09-24
ES2257756T3 (es) 2006-08-01
EP0795334B1 (fr) 2006-02-01
CA2199664C (fr) 2008-05-20
PL189604B1 (pl) 2005-08-31
US5935995A (en) 1999-08-10
JPH101495A (ja) 1998-01-06
SI0795334T1 (sl) 2006-06-30
EP0795334A2 (fr) 1997-09-17
TR199700178A2 (tr) 1997-09-21
CZ74297A3 (en) 1997-09-17
HU9700579D0 (en) 1997-04-28
CA2199664A1 (fr) 1997-09-12
BR9701248A (pt) 1999-10-13
HU228764B1 (en) 2013-05-28
UA50719C2 (uk) 2002-11-15
CZ297994B6 (cs) 2007-05-16
RO120951B1 (ro) 2006-10-30
NO971116L (no) 1997-09-15
KR100466467B1 (ko) 2005-06-29
PL318878A1 (en) 1997-09-15
HUP9700579A3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
BG61900B1 (bg) Нови пролекарства за терапия на тумори и възпалителнизаболявания
EP2041140B1 (fr) Composés aziridinyl-epothilone
US6146658A (en) Prodrugs, their preparation and use as pharmaceuticals
US20070275904A1 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
US9872919B2 (en) Prodrugs for selective anticancer therapy
ES2494765T3 (es) Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
US10772881B2 (en) Quinolines that modulate SERCA and their use for treating disease
US20220041577A1 (en) Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor
US11890279B2 (en) Quinolines that modulate SERCA and their use for treating disease
Cardona-G et al. Chemistry and anticancer activity of hybrid molecules and derivatives based on 5-fluorouracil
AU2017273871B2 (en) Polymer linkers and their uses
JP5649647B2 (ja) 酸に不安定なトリガーユニット
US11987579B2 (en) Niclosamide analogues and therapeutic use thereof
MXPA97001832A (en) New profarmacos for inflamator tumors and disease therapy
US10266547B2 (en) Thieno[2,3-e]indole derivatives as new antitumor agents
KR100429356B1 (ko) 다약제 내성 극복 이소퀴놀린계 화합물 및 그 제조방법
KR100596361B1 (ko) 항암 활성을 갖는 신규 2-옥소-피페리딘 유도체（ⅱ）화합물을 포함하는 암 질환 치료를 위한 약학 조성물
ZA200004087B (en) Novel therapeutic agents that modulate alpha-1A adrenergic receptors.